Celgene Corporation

Registered Principal Details

Business Or Interest:
Biopharmaceutical company.

Lobbying Interests:
Health care access to pharmaceuticals, biotechnology issues, and cancer drug repository programs.

CEO Name:
Bob Hugin
Vice President

Contact
AMF
Anne Marie Finley
86 Morris Ave
Summit, NJ 07901
(908) 337-4682
www.celgene.com

Authorized Lobbyists

Lobbyist Name Exclusive Duties Authorized On Withdrawn On
Greg Chesmore Exclusive Duties N/A Authorized On 1/1/2011 Withdrawn On N/A
Kelly McDowell Exclusive Duties N/A Authorized On 1/1/2011 Withdrawn On N/A

Lobbying Interests

Legislative Bills/Resolutions

Assembly Bill 151
Assembly Bill 151
Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy.

Bill Text and History

For
Notification Date
5/26/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Comments
Ensure patient access to FDA-approved oral chemotherapy within health plans that currently cover chemotherapy.
Senate Bill 101
Senate Bill 101
Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy.

Bill Text and History

For
Notification Date
5/26/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Comments
Ensure patient access to FDA-approved oral chemotherapy within health plans that currently cover chemotherapy.

Topics Not Yet Assigned A Bill Or Rule Number

Resolution recognizing the importance of placenta-cord blood banking and research utilizing placenta-cord blood stem cells; Calling for increased public awareness about the option of banking placenta and cord blood.
Development, drafting or introduction of a proposal relating to
Resolution recognizing the importance of placenta-cord blood banking and research utilizing placenta-cord blood stem cells; Calling for increased public awareness about the option of banking placenta and cord blood.

Action Intended To Affect
Legislative Matter

Notification Date
3/27/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Bills to revamp Wisconsin's cancer and chronic disease drug repository program.
Development, drafting or introduction of a proposal relating to
Bills to revamp Wisconsin's cancer and chronic disease drug repository program.

Action Intended To Affect
Legislative Matter

Notification Date
1/1/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Seeking agency action within the Department of Health Services to ensure that FDA-mandated restricted distribution drugs are not accepted and redispensed in violation of FDA risk management programs.
Development, drafting or introduction of a proposal relating to
Seeking agency action within the Department of Health Services to ensure that FDA-mandated restricted distribution drugs are not accepted and redispensed in violation of FDA risk management programs.

Action Intended To Affect
Rule (by a state agency)

Notification Date
1/1/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

The lack of necessity for new laws restricting the access of pharmaceutical sales representatives and promoting the role these professionals have working with physicians to ensure patient access to needed drugs.
Development, drafting or introduction of a proposal relating to
The lack of necessity for new laws restricting the access of pharmaceutical sales representatives and promoting the role these professionals have working with physicians to ensure patient access to needed drugs.

Action Intended To Affect
Legislative Matter

Notification Date
1/1/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Draft resolution regarding placenta blood/cord blood banking and research.
Development, drafting or introduction of a proposal relating to
Draft resolution regarding placenta blood/cord blood banking and research.

Action Intended To Affect
Legislative Matter

Notification Date
1/1/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Oral Oncology Fairness: legislation requiring coverage of oral cancer therapies to be no less favorable than injectable/IV therapies.
Development, drafting or introduction of a proposal relating to
Oral Oncology Fairness: legislation requiring coverage of oral cancer therapies to be no less favorable than injectable/IV therapies.

Action Intended To Affect
Legislative Matter

Notification Date
1/1/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Potential Assembly Resolution regarding public awareness of cord blood/placenta blood banking and research.
Development, drafting or introduction of a proposal relating to
Potential Assembly Resolution regarding public awareness of cord blood/placenta blood banking and research.

Action Intended To Affect
Legislative Matter

Notification Date
1/1/2011
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Total Lobbying Effort

  2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
Total Lobbying Expenditures 2011
January - June
$30,967.16
2011
July - December
$29,479.03
2012
January - June
$26,908.49
2012
July - December
$25,943.50
Total $113,298.18
Total Hours Communicating 2011
January - June
101.50
2011
July - December
50.75
2012
January - June
28.50
2012
July - December
1.00
Total 181.75
Total Hours Other 2011
January - June
133.50
2011
July - December
111.75
2012
January - June
49.00
2012
July - December
63.50
Total 357.75

Percent Allocation of Lobbying Effort

Legislative Bills/Resolutions

Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy.
2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
2011
January - June
50 %
2011
July - December
50 %
2012
January - June
50 %
2012
July - December
50 %
Total 50 %
Relating to: copayments, deductibles, or coinsurance for oral chemotherapy and injected or intravenous chemotherapy.
2011
January - June
2011
July - December
2012
January - June
2012
July - December
Total
2011
January - June
50 %
2011
July - December
50 %
2012
January - June
50 %
2012
July - December
50 %
Total 50 %

Budget Bill Subjects

No budget bill subjects found.

Administrative Rulemaking Proceedings

No administrative rulemaking proceedings found.

Topics Not Yet Assigned A Bill Or Rule Number

No topics found.

Minor Efforts

No minor efforts found.

Other Matters

No other matters found.

Filed Statements of Lobbying Activity and Expenditures